Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review.

Choi JS, Sansoni ER, Lovin BD, Lindquist NR, Phan J, Mayo LL, Ferrarotto R, Su SY.

Ann Otol Rhinol Laryngol. 2019 Dec 25:3489419896602. doi: 10.1177/0003489419896602. [Epub ahead of print]

PMID:
31875405
2.

A prospective evaluation of health-related quality of life after skull base re-irradiation.

Bahig H, Ng SP, Pollard C 3rd, Nguyen TP, Gunn GB, Rosenthal DI, Fuller CD, Frank SJ, Garden AS, Reddy JP, Morrison WH, Ferrarotto R, Hanna EY, DeMonte F, Su SY, Phan J.

Head Neck. 2019 Dec 23. doi: 10.1002/hed.26037. [Epub ahead of print]

PMID:
31868271
3.

Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma.

Pestana RC, Becnel M, Rubin ML, Torman DK, Crespo J, Phan J, Hanna E, Bell D, Glisson BS, Johnson JM, Lee JJ, Ferrarotto R.

Oral Oncol. 2019 Dec 18;101:104523. doi: 10.1016/j.oraloncology.2019.104523. [Epub ahead of print]

PMID:
31864957
4.

Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck.

Tam S, Yao CMK, Amit M, Gajera M, Luo X, Treistman R, Khanna A, Aashiq M, Nagarajan P, Bell D, El-Naggar A, Migden M, Wong M, Glisson B, Ferrarotto R, Esmaeli B, Rosenthal D, Li G, Weber RS, Myers JN, Gross ND.

JAMA Otolaryngol Head Neck Surg. 2019 Dec 5. doi: 10.1001/jamaoto.2019.3751. [Epub ahead of print]

PMID:
31804658
5.

Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.

Mitani Y, Lin SH, Pytynia KB, Ferrarotto R, El-Naggar AK.

Clin Cancer Res. 2019 Nov 26. pii: clincanres.1603.2019. doi: 10.1158/1078-0432.CCR-19-1603. [Epub ahead of print]

PMID:
31772120
6.

Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting.

Sandulache VC, Lei YL, Heasley LE, Chang M, Amos CI, Sturgis EM, Graboyes E, Chiao EY, Rogus-Pulia N, Lewis J, Madabhushi A, Frederick MJ, Sabichi A, Ittmann M, Yarbrough WG, Chung CH, Ferrarotto R, Mai W, Skinner HD, Duvvuri U, Gerngross P, Sikora AG.

Oral Oncol. 2019 Oct 21:104440. doi: 10.1016/j.oraloncology.2019.104440. [Epub ahead of print] No abstract available.

PMID:
31648864
7.

Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy.

Ng SP, Pollard C 3rd, Kamal M, Ayoub Z, Garden AS, Bahig H, Gunn GB, Frank SJ, Skinner HD, Phan J, Berends J, Morrison WH, Johnson JM, Ferrarotto R, Sturgis EM, Mohamed ASR, Lai SY, Fuller CD, Rosenthal DI.

NPJ Precis Oncol. 2019 Sep 27;3:22. doi: 10.1038/s41698-019-0097-y. eCollection 2019.

8.

Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer.

Hutcheson KA, Warneke CL, Yao CMKL, Zaveri J, Elgohari BE, Goepfert R, Hessel AC, Kupferman ME, Lai SY, Fuller CD, Gunn GB, Garden AS, Johnson F, Ferrarotto R, Lewin JS, Gross ND; MD Anderson Head and Neck Cancer Symptom Working Group.

JAMA Otolaryngol Head Neck Surg. 2019 Sep 26. doi: 10.1001/jamaoto.2019.2725. [Epub ahead of print]

PMID:
31556933
9.

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.

Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW.

J Immunother Cancer. 2019 Sep 4;7(1):237. doi: 10.1186/s40425-019-0718-6.

10.

Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy.

Bagley AF, Ye R, Garden AS, Gunn GB, Rosenthal DI, Fuller CD, Morrison WH, Phan J, Sturgis EM, Ferrarotto R, Wu R, Liu AY, Frank SJ.

Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33002-6. doi: 10.1016/j.radonc.2019.07.012. [Epub ahead of print]

PMID:
31431373
11.

Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.

Bell D, Ferrarotto R, Liang L, Goepfert RP, Li J, Ning J, Broaddus R, Weber RS, El-Naggar AK.

Virchows Arch. 2019 Aug 19. doi: 10.1007/s00428-019-02640-7. [Epub ahead of print]

PMID:
31423558
12.

Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review.

Shah M, Jomaa MK, Ferrarotto R, Yeung SJ, Hanna EY, Reyes-Gibby CC.

Head Neck. 2019 Nov;41(11):4036-4050. doi: 10.1002/hed.25911. Epub 2019 Aug 15. Review.

PMID:
31414560
13.

Ectopic ACTH Production and Cushing's Syndrome in a Patient with Parotid Acinic Cell Carcinoma with High-Grade Transformation: Tumor Context and Clinical Implications.

Saluja K, Ravishankar S, Ferrarotto R, Zhu H, Pytynia KB, El-Naggar AK.

Head Neck Pathol. 2019 Jul 30. doi: 10.1007/s12105-019-01054-w. [Epub ahead of print]

PMID:
31363907
14.

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.

Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME.

Thyroid. 2019 Aug;29(8):1036-1043. doi: 10.1089/thy.2019.0133.

15.

Magnifying glass on spiradenoma and cylindroma histogenesis and tumorigenesis using systematic transcriptome analysis.

Bell AH, Prieto VG, Ferrarotto R, Goepfert RP, Myers JN, Weber R, Bell D.

Ann Diagn Pathol. 2019 Aug;41:14-23. doi: 10.1016/j.anndiagpath.2019.04.015. Epub 2019 May 5.

PMID:
31128548
16.

PD-L1 expression by immunohistochemistry in salivary duct carcinoma.

Hamza A, Roberts D, Su S, Weber RS, Bell D, Ferrarotto R.

Ann Diagn Pathol. 2019 Jun;40:49-52. doi: 10.1016/j.anndiagpath.2019.04.001. Epub 2019 Apr 3.

PMID:
30978575
17.

Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy.

Ng SP, Pollard C 3rd, Berends J, Ayoub Z, Kamal M, Garden AS, Bahig H, Cantor SB, Schaefer AJ, Ajayi T, Gunn GB, Frank SJ, Skinner H, Phan J, Morrison WH, Ferrarotto R, Johnson JM, Mohamed ASR, Lai SY, Hessel AC, Sturgis EM, Weber RS, Fuller CD, Rosenthal DI.

Cancer. 2019 Jun 1;125(11):1823-1829. doi: 10.1002/cncr.31983. Epub 2019 Feb 12.

PMID:
30748005
18.

Long-term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies.

Tyler MA, Mohamed ASR, Smith JB, Aymard JM, Fuller CD, Phan J, Frank SJ, Ferrarotto R, Kupferman ME, Hanna EY, Gunn GB, Su SY.

Laryngoscope. 2020 Jan;130(1):86-93. doi: 10.1002/lary.27849. Epub 2019 Feb 1.

PMID:
30706478
19.

Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma.

Amit M, Abdelmeguid AS, Watcherporn T, Takahashi H, Tam S, Bell D, Ferrarotto R, Glisson B, Kupferman ME, Roberts DB, Su SY, Raza SM, DeMonte F, Hanna EY.

J Clin Oncol. 2019 Feb 20;37(6):504-512. doi: 10.1200/JCO.18.00353. Epub 2019 Jan 7.

20.

PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.

Ibrahim MY, Nunez MI, Harun N, Lee JJ, El-Naggar AK, Ferrarotto R, Wistuba I, Myers J, Glisson BS, William WN Jr.

Head Neck. 2019 Mar;41(3):615-622. doi: 10.1002/hed.25350. Epub 2018 Dec 16.

PMID:
30556200
21.

Salivary gland tumors: Molecular characterization and therapeutic advances for metastatic disease.

Schvartsman G, Pinto NA, Bell D, Ferrarotto R.

Head Neck. 2019 Jan;41(1):239-247. doi: 10.1002/hed.25468. Epub 2018 Dec 15. Review.

PMID:
30552848
22.

Prognostic factors and survival in adenoid cystic carcinoma of the sinonasal cavity.

Mays AC, Hanna EY, Ferrarotto R, Phan J, Bell D, Silver N, Mulcahy CF, Roberts D, Abdelmeguid ASA, Fuller CD, Frank SJ, Raza SM, Kupferman ME, DeMonte F, Su SY.

Head Neck. 2018 Dec;40(12):2596-2605. doi: 10.1002/hed.25335. Epub 2018 Nov 17.

PMID:
30447126
23.

Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma.

Sagiv O, Ding S, Ferrarotto R, Glisson B, Altan M, Johnson F, Elamin Y, Thakar SD, Nagarajan P, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2019 Jul/Aug;35(4):350-353. doi: 10.1097/IOP.0000000000001251.

PMID:
30365473
24.

Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.

Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH, El-Naggar AK.

Cancer. 2018 Sep 15;124(18):3693-3705. doi: 10.1002/cncr.31600. Epub 2018 Oct 5.

25.

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.

Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, Haymaker C, Bernatchez C, Curran M, Zecchini Barrese T, Rodriguez Canales J, Wistuba I, Li L, Wang J, van der Burg SH, Melief CJ, Glisson B.

JAMA Oncol. 2019 Jan 1;5(1):67-73. doi: 10.1001/jamaoncol.2018.4051.

26.

Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling.

Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, Skinner HD, Gunn GB, Garden AS, Phan J, Rosenthal DI, Morrison WH, Frank SJ, Hutcheson KA, Mohamed ASR, Lai SY, Ferrarotto R, MacManus MP, Fuller CD.

BMC Cancer. 2018 Sep 19;18(1):903. doi: 10.1186/s12885-018-4808-5.

27.

Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma.

Sagiv O, Nagarajan P, Ferrarotto R, Kandl TJ, Thakar SD, Glisson BS, Altan M, Esmaeli B.

Br J Ophthalmol. 2019 Jun;103(6):775-780. doi: 10.1136/bjophthalmol-2018-312277. Epub 2018 Jul 18.

28.

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.

Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME.

J Immunother Cancer. 2018 Jul 11;6(1):68. doi: 10.1186/s40425-018-0378-y.

29.

Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry.

Kamal M, Mohamed ASR, Volpe S, Zaveri J, Barrow MP, Gunn GB, Lai SY, Ferrarotto R, Lewin JS, Rosenthal DI, Jethanandani A, Meheissen MAM, Mulder SL, Cardenas CE, Fuller CD, Hutcheson KA; MD Anderson Head, Neck Cancer Symptom Working Group.

Radiother Oncol. 2018 Sep;128(3):442-451. doi: 10.1016/j.radonc.2018.06.013. Epub 2018 Jun 28.

30.

Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.

Ferrarotto R, William WN Jr, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Jack Lee J, Wistuba IW, Haddad RI, Glisson BS.

Oral Oncol. 2018 Jul;82:83-90. doi: 10.1016/j.oraloncology.2018.05.014. Epub 2018 May 19.

PMID:
29909907
31.

Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy.

Mott FE, Ferrarotto R, Nguyen T, Phan J.

Oral Oncol. 2018 Jun;81:75-80. doi: 10.1016/j.oraloncology.2018.04.020.

PMID:
29884417
32.

Age-adjusted comorbidity and survival in locally advanced laryngeal cancer.

Multidisciplinary Larynx Cancer Working Group, Mulcahy CF, Mohamed ASR, Kanwar A, Hutcheson KA, Ghosh A, Vock D, Weber RS, Lai SY, Gunn GB, Zafereo M, Morrison WH, Ferrarotto R, Garden AS, Rosenthal DI, Fuller CD.

Head Neck. 2018 Sep;40(9):2060-2069. doi: 10.1002/hed.25200. Epub 2018 May 13.

33.

Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.

Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M.

Thyroid. 2018 Jul;28(7):945-951. doi: 10.1089/thy.2018.0060. Epub 2018 Jun 29.

34.

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.

Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P.

Ann Oncol. 2018 Jul 1;29(7):1561-1568. doi: 10.1093/annonc/mdy171.

PMID:
29726923
35.

Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer.

Kamal M, Ng SP, Eraj SA, Rock CD, Pham B, Messer JA, Garden AS, Morrison WH, Phan J, Frank SJ, El-Naggar AK, Johnson JM, Ginsberg LE, Ferrarotto R, Lewin JS, Hutcheson KA, Cardenas CE, Zafereo ME, Lai SY, Hessel AC, Weber RS, Gunn GB, Fuller CD, Mohamed ASR, Rosenthal DI.

Oral Oncol. 2018 Apr;79:1-8. doi: 10.1016/j.oraloncology.2018.01.025. Epub 2018 Feb 10.

36.

Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.

Ferrarotto R, Cardnell R, Su S, Diao L, Eterovic AK, Prieto V, Morrisson WH, Wang J, Kies MS, Glisson BS, Byers LA, Bell D.

Head Neck. 2018 Aug;40(8):1676-1684. doi: 10.1002/hed.25146. Epub 2018 Mar 23.

37.

The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.

Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S.

J Natl Cancer Inst. 2018 Aug 1;110(8):888-894. doi: 10.1093/jnci/djx288.

PMID:
29346573
38.

Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy.

Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, Volpe S, Ng SP, Ferrarotto R, Frank SJ, Skinner HD, Rosenthal DI, Garden AS.

Cancer. 2018 Apr 1;124(7):1415-1427. doi: 10.1002/cncr.31235. Epub 2018 Jan 16.

39.

Recent advances and emerging therapies in anaplastic thyroid carcinoma.

Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL.

F1000Res. 2018 Jan 18;7. pii: F1000 Faculty Rev-87. doi: 10.12688/f1000research.13124.1. eCollection 2018. Review.

40.

Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb.

Mays AC, Bell D, Ferrarotto R, Phan J, Roberts D, Fuller CD, Frank SJ, Raza SM, Kupferman ME, DeMonte F, Hanna EY, Su SY.

Laryngoscope. 2018 Jun;128(6):1274-1280. doi: 10.1002/lary.26908. Epub 2017 Dec 11.

PMID:
29226334
41.

Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old.

MD Anderson Head and Neck Cancer Symptom Working Group, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Brandon Gunn G.

Radiat Oncol. 2017 Nov 23;12(1):186. doi: 10.1186/s13014-017-0921-x.

42.

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.

Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME.

Thyroid. 2018 Jan;28(1):79-87. doi: 10.1089/thy.2017.0285. Epub 2017 Dec 21.

43.

Taking it up a NOTCH: a novel subgroup of ACC is identified.

Ferrarotto R, Heymach JV.

Oncotarget. 2017 Sep 14;8(47):81725-81726. doi: 10.18632/oncotarget.20879. eCollection 2017 Oct 10. No abstract available.

44.

Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.

William WN Jr, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, Glisson B, Kim ES.

J Am Acad Dermatol. 2017 Dec;77(6):1110-1113.e2. doi: 10.1016/j.jaad.2017.07.048. Epub 2017 Sep 28.

45.

Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old.

MD Anderson Head and Neck Cancer Symptom Working Group, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Gunn GB.

Radiat Oncol. 2017 Sep 9;12(1):150. doi: 10.1186/s13014-017-0878-9. Erratum in: Radiat Oncol. 2017 Nov 23;12 (1):186.

46.

Outcomes for olfactory neuroblastoma treated with induction chemotherapy.

Su SY, Bell D, Ferrarotto R, Phan J, Roberts D, Kupferman ME, Frank SJ, Fuller CD, Gunn GB, Kies MS, Glisson BS, Hanna EY.

Head Neck. 2017 Aug;39(8):1671-1679. doi: 10.1002/hed.24822. Epub 2017 May 31.

PMID:
28561956
47.

Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx.

Shiao JC, Mohamed ASR, Messer JA, Hutcheson KA, Johnson JM, Enderling H, Kamal M, Warren BW, Pham B, Morrison WH, Zafereo ME, Hessel AC, Lai SY, Kies MS, Ferrarotto R, Garden AS, Schomer DF, Gunn GB, Phan J, Frank SJ, Beadle BM, Weber RS, Lewin JS, Rosenthal DI, Fuller CD.

Head Neck. 2017 Aug;39(8):1609-1620. doi: 10.1002/hed.24804. Epub 2017 May 2.

48.

Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.

Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME.

Thyroid. 2017 May;27(5):672-681. doi: 10.1089/thy.2016.0395. Epub 2017 Feb 16.

49.

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.

Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV.

J Clin Oncol. 2017 Jan 20;35(3):352-360. doi: 10.1200/JCO.2016.67.5264. Epub 2016 Nov 21.

50.

Checkpoint inhibitors in lung cancer: latest developments and clinical potential.

Schvartsman G, Ferrarotto R, Massarelli E.

Ther Adv Med Oncol. 2016 Nov;8(6):460-473. Epub 2016 Jul 26. Review.

Supplemental Content

Loading ...
Support Center